Reducing Cardiovascular Disease Risk Through Treatment of Obstructive Sleep Apnea (U34)

The summary for the Reducing Cardiovascular Disease Risk Through Treatment of Obstructive Sleep Apnea (U34) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Reducing Cardiovascular Disease Risk Through Treatment of Obstructive Sleep Apnea (U34): Purpose. The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) solicits three-year Clinical Trials Planning Grant Cooperative Agreement (U34) applications from institutions or organizations for pilot studies evaluating the treatment of obstructive sleep apnea (OSA) using positive airway pressure (PAP). The purposes of these studies are twofold. First, the studies should be designed to provide information regarding feasibility of long-term (12 to 18 months) PAP treatment of OSA in patients at risk of CVD. Second, the studies should provide data regarding the effects of PAP on surrogate markers of cardiovascular risk. Outcomes relevant for this FOA are broad and include a range of feasibility metrics (recruitment, retention, randomization, dose of PAP treatment, and design of control groups) and adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to PAP treatment); sympathetic nervous system hyperactivity; vascular dysfunction; inflammatory markers; platelet aggregation; and neuroendocrine and metabolic function. Populations that are at high risk for cardiovascular disease with established OSA and no prior history of PAP treatment will be the central focus of this initiative. Specific goals are to establish feasibility of long-term PAP treatment in high-risk individuals, to evaluate the potential for such treatment to produce changes in cardiovascular disease risk profiles, and to identify feasibility of study design strategies for future event-driven Phase III clinical trials.
Federal Grant Title: Reducing Cardiovascular Disease Risk Through Treatment of Obstructive Sleep Apnea (U34)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HL-10-023
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.233
CFDA Descriptions: National Center on Sleep Disorders Research
Current Application Deadline: Jan 21, 2010
Original Application Deadline: Jan 21, 2010
Posted Date: Nov 27, 2009
Creation Date: Nov 27, 2009
Archive Date: Feb 21, 2010
Total Program Funding: $1,500,000
Maximum Federal Grant Award: $650,000
Minimum Federal Grant Award:
Expected Number of Awards: 2
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB...
Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB...
Catalyze: Product Definition Device Prototype Testing and Design Modification, Diagnostic ...
Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trial...
Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and...
Ancillary Studies in Clinical Trials (R01)
Opportunity PA-08-021
Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com